Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
Tumorvirus-specific Vaccination Strategies

Dr. Filipe Mariz, post-doc



CUT-PANHPVAX -a vaccine against cutaneous human papillomaviruses-


Organ transplant recipients submitted to immunosuppression are hugely susceptible to devel-op massive, recurrent cutaneous warts due to infection by types of human papillomavirus typically colonizing the skin, i.e. cutaneous HPV types. Current papillomavirus vaccines do not protect against this subgroup of papillomavirus. The lesions then require repeated and costly treatments – which do not provide lasting cure – and often they progress to carcinomas in transplant recipients, although the carcinogenic role of cutaneous papillomaviruses has not been formally proved. Building on our recent success to develop and evaluate PANHPVAX, a related vaccine targeting mucosal HPV, in a Phase I trial, we have adopted the same cost-effective, thermostable and modular vaccine platform to generate vaccine against cutaneous papillomaviruses able.


Seeking a cost-efficient and broadly protective prophylactic vaccine against cHPV infection, we are currently assessing the effectiveness of HPV L2 polytopes fused to the bacterial Thioredoxin (Trx) scaffold protein as candidate vaccines in animal model. Of particular interest, the influence of a heptamerization domain (IMX313) in boosting both antibody and T-helper responses of the designed candidates is also under investigation.

Further information:

A Broadly Protective Vaccine against Cutaneous Human Papillomaviruses. (2022)
Filipe Mariz, Kathrin Balz, Manuela Dittrich, Yueru Zhang, Fan Yang, Xueer Zhao, Angelo Bolchi, Simone Ottonello, and Martin Müller. In press. A Broadly Protective Vaccine against Cutaneous Human Papillomaviruses. npj Vaccines, in press.

to top
powered by webEdition CMS